Bezlotoxumab for Prevention of Recurrent<i>Clostridiu

New England Journal of Medicine
376, 305-317
DOI: 10.1056/nejmoa1602615

Citation Report

#	Article	IF	Citations
1	Bezlotoxumab â€" A New Agent forClostridium difficileInfection. New England Journal of Medicine, 2017, 376, 381-382.	13.9	27
2	Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery, 2017, 162, 325-348.	1.0	103
3	Emerging monoclonal antibodies againstClostridium difficileinfection. Expert Opinion on Biological Therapy, 2017, 17, 415-427.	1.4	14
4	Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohort. Anaerobe, 2017, 44, 117-123.	1.0	42
5	Modifying recurrence of Clostridium difficile infection. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 137-137.	8.2	1
6	Reducing Recurrence of C. difficile Infection. Cell, 2017, 169, 375.	13.5	30
7	Bezlotoxumab and Recurrent Clostridium difficile Infection. New England Journal of Medicine, 2017, 376, 1593-1596.	13.9	13
9	Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?. Annals of Pharmacotherapy, 2017, 51, 804-810.	0.9	15
11	Collateral damage during antibiotic treatment ofC. difficileinfection in the aged host: Insights into why recurrent disease happens. Gut Microbes, 2017, 8, 504-510.	4.3	4
12	Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. Journal of Antimicrobial Chemotherapy, 2017, 72, 2647-2656.	1.3	54
13	Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Scientific Reports, 2017, 7, 3665.	1.6	34
14	How to: Establish and run a stool bank. Clinical Microbiology and Infection, 2017, 23, 924-930.	2.8	120
15	Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence ofClostridium difficileinfection. Expert Review of Gastroenterology and Hepatology, 2017, 11, 611-622.	1.4	11
17	Clostridium difficile infection in solid organ transplant recipients. Current Opinion in Organ Transplantation, 2017, 22, 314-319.	0.8	11
18	Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2017, 65, 1396-1399.	2.9	51
19	Clostridium difficile. Clinics in Laboratory Medicine, 2017, 37, 341-369.	0.7	28
20	Preventing the spread of infectious diseases: antivirulents versus antibiotics. Future Microbiology, 2017, 12, 365-368.	1.0	7
21	Clostridium difficile in Older Adults. Infectious Disease Clinics of North America, 2017, 31, 743-756.	1.9	23

#	Article	IF	Citations
22	Clostridium difficileinfection: new approaches to prevention, non-antimicrobial treatment, and stewardship. Expert Review of Anti-Infective Therapy, 2017, 15, 1027-1040.	2.0	19
23	The role of toxins in Clostridium difficile infection. FEMS Microbiology Reviews, 2017, 41, 723-750.	3.9	231
24	Prediction of RecurrentClostridium DifficileInfection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System. Infection Control and Hospital Epidemiology, 2017, 38, 1196-1203.	1.0	36
25	Adaptive immune constraints on C. difficile vaccination. Expert Review of Vaccines, 2017, 16, 1053-1055.	2.0	2
26	Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence. Drugs, 2017, 77, 1657-1663.	4.9	15
27	Clostridium difficile. Medicine, 2017, 45, 634-638.	0.2	1
28	Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection. Pharmacotherapy, 2017, 37, 1298-1308.	1.2	30
29	Les vaccins dans la prÃ©vention des infections associÃ©es aux soins. Journal Des Anti-infectieux, 2017, 19, 134-146.	0.1	0
30	The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 5-7.	1.2	0
31	Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface. Journal of Biological Chemistry, 2017, 292, 14401-14412.	1.6	10
32	Clostridium Difficile, Colitis, and Colonoscopy: Pediatric Perspective. Current Gastroenterology Reports, 2017, 19, 34.	1.1	5
33	Therapy for Clostridium difficile infection â€“ any news beyond Metronidazole and Vancomycin?. Expert Review of Clinical Pharmacology, 2017, 10, 1239-1250.	1.3	10
34	Nonantimicrobial drug targets for Clostridium difficile infections. Future Microbiology, 2017, 12, 975-985.	1.0	6
35	Bezlotoxumab for the prevention ofClostridium difficilerecurrence. Expert Opinion on Biological Therapy, 2017, 17, 1-7.	1.4	6
36	Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection. Clinical Infectious Diseases, 2017, 65, 1218-1221.	2.9	18
37	Choice of treatment in Clostridium difficile -associated diarrhoea: Clinical practice guidelines (CPGs) or risk classifications. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 613-616.	0.2	0
38	Effect of Oral Capsuleâ€“ vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection. JAMA - Journal of the American Medical Association, 2017, 318, 1985.	3.8	446
40	EleccÃ³n del tratamiento en la diarrea asociada a Clostridium difficile: guÃas de prÃ¡ctica clÃnica o clasificaciones de riesgo. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 613-616.	0.3	2

#	Article	IF	Citations
41	Anti-bacterial Monoclonal Antibodies. Advances in Experimental Medicine and Biology, 2017, 1053, 119-153.	0.8	22
44	Clostridium difficile infection in the elderly: an update on management. Clinical Interventions in Aging, 2017, Volume 12, 1799-1809.	1.3	73
45	A Review of the Safety and Efficacy of Vaccines as Prophylaxis for Clostridium difficile Infections. Vaccines, 2017, 5, 25.	2.1	25
46	Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infection and Drug Resistance, 2017, Volume 10, 365-375.	1.1	14
48	Â«Mikrobiota-TuningÂ» en vogue: Von der ErnÃhrung Ã¼ber Probiotika bis zur fÃkalen Mikrobiota-Transplantation. Schweizerische Zeitschrift FÃ¼r GanzheitsMedizin, 2017, 29, 144-148.	0.0	1
49	A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection. Open Forum Infectious Diseases, 2017, 4, ofx235.	0.4	11
50	Treatment of recurrent Clostridium difficile colitis: a narrative review. Gastroenterology Report, 2018, 6, 21-28.	0.6	45
51	New and emerging therapies in treatment of Clostridium difficile infection. European Journal of Gastroenterology and Hepatology, 2018, 30, 589-597.	0.8	5
52	Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
53	Infectious Diseases in Older Adults of Longâ€Term Care Facilities: Update on Approach to Diagnosis and Management. Journal of the American Geriatrics Society, 2018, 66, 789-803.	1.3	64
54	Managing Clostridium Difficile: An Old Bug With New Tricks. American Journal of Gastroenterology, 2018, 113, 932-935.	0.2	3
55	Quantitative Thresholds Enable Accurate Identification of Clostridium difficile Infection by the Luminex xTAG Gastrointestinal Pathogen Panel. Journal of Clinical Microbiology, 2018, 56, .	1.8	7
56	Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting. Infection and Immunity, 2018, 86, .	1.0	6
57	Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut, 2018, 67, 1380-1399.	6.1	197
58	Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infectious Diseases and Therapy, 2018, 7, 71-86.	1.8	45
59	(Some) current concepts in antibacterial drug discovery. Applied Microbiology and Biotechnology, 2018, 102, 2949-2963.	1.7	15
60	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, e1-e48.	2.9	1,695
61	Immunization Strategies Against Clostridium difficile. Advances in Experimental Medicine and Biology, 2018, 1050, 197-225.	0.8	13

#	Article	IF	Citations
62	European Practice for CDI Treatment. Advances in Experimental Medicine and Biology, 2018, 1050, 117-135.	0.8	9
63	Bezlotoxumab. Infectious Diseases in Clinical Practice, 2018, 26, 60-65.	0.1	0
64	Clostridium difficile control measures: current and future methods for prevention. Expert Review of Anti-Infective Therapy, 2018, 16, 121-131.	2.0	15
65	Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy. European Journal of Immunology, 2018, 48, 398-406.	1.6	22
66	Update of treatment algorithms for Clostridium difficile infection. Clinical Microbiology and Infection, 2018, 24, 452-462.	2.8	103
67	Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infectious Diseases, The, 2018, 18, 296-307.	4.6	141
68	Exploring ways to improve CDI outcomes. MÃ©decine Et Maladies Infectieuses, 2018, 48, 10-17.	5.1	2
69	Tackling the recurrence of Clostridium difficile infection. MÃ©decine Et Maladies Infectieuses, 2018, 48, 18-22.	5.1	16
70	Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe, 2018, 49, 103-111.	1.0	14
71	The role of vaccines in preventing bacterial antimicrobial resistance. Nature Medicine, 2018, 24, 10-19.	15.2	228
72	Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2018, 66, 355-362.	2.9	55
74	Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 756-761.	1.0	6
75	Vaccines for healthcare-associated infections: present, future, and expectations. Expert Review of Vaccines, 2018, 17, 421-433.	2.0	25
76	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660â€"A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2018, 67, 1198-1204.	2.9	96
77	Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. Journal of Hospital Infection, 2018, 99, 436-442.	1.4	93
79	New insights into transmission of Clostridium difficile infectionâ€"narrative review. Clinical Microbiology and Infection, 2018, 24, 483-492.	2.8	41
80	Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?. Expert Opinion on Biological Therapy, 2018, 18, 469-476.	1.4	5
81	Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	23

#	Article	IF	Citations
82	Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection. Infectious Diseases: Research and Treatment, 2018, 11, 117863371875802.	0.7	10
83	Engineering therapeutic antibodies to combat infectious diseases. Current Opinion in Chemical Engineering, 2018, 19, 131-141.	3.8	28
84	Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clinical Infectious Diseases, 2018, 67, 649-656.	2.9	143
85	Understanding Clostridium difficile Colonization. Clinical Microbiology Reviews, 2018, 31, .	5.7	206
86	Beyond binding: antibody effector functions in infectious diseases. Nature Reviews Immunology, 2018, 18, 46-61.	10.6	516
87	Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. International Journal of Antimicrobial Agents, 2018, 51, 393-398.	1.1	38
88	Clostridium difficile : What the surgeon needs to know. Seminars in Colon and Rectal Surgery, 2018, 29, 28-36.	0.2	3
89	The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients. Journal of Infection and Chemotherapy, 2018, 24, 123-129.	0.8	17
90	Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2018, 97, 31-49.	0.8	31
91	A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells. Journal of Biological Chemistry, 2018, 293, 941-952.	1.6	27
93	Narrow-spectrum antibacterial agents. MedChemComm, 2018, 9, 12-21.	3.5	135
94	The Revolving (Bathroom) Door. , 2018, , 239-244.		0
95	Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure. Clinical Infectious Diseases, 2018, 66, 134-135.	2.9	38
96	Clostridium Difficile. Nepalese Medical Journal, 2018, 1, 43-46.	0.0	1
98	Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. Journal of Clinical Oncology, 2018, 36, 3162-3171.	0.8	25
99	496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment. Open Forum Infectious Diseases, 2018, 5, S183-S184.	0.4	0
100	1093. Single Molecule Counting Technology for Ultrasensitive Quantification of Clostridium difficile Toxins A and B. Open Forum Infectious Diseases, 2018, 5, S327-S327.	0.4	4
101	Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile. Frontiers in Microbiology, 2018, 9, 2908.	1.5	18

#	Article	IF	Citations
102	Ridinilazoleâ€"a novel antibiotic for treatment of Clostridium difficile infection. Journal of Thoracic Disease, 2018, 10, 118-120.	0.6	4
103	The Conserved Cys-2232 in Clostridioides difficile Toxin B Modulates Receptor Binding. Frontiers in Microbiology, 2018, 9, 2314.	1.5	20
105	Current Status of <I>Clostridium Difficile</I> Infection. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 456-469.	0.1	1
106	Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections. Beilstein Journal of Organic Chemistry, 2018, 14, 2607-2617.	1.3	67
107	â–¼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection. Drug and Therapeutics Bulletin, 2018, 56, 57-60.	0.3	1
109	Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. Open Forum Infectious Diseases, 2018, 5, ofy218.	0.4	7
110	Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile. Infection and Drug Resistance, 2019, Volume 12, 1-9.	1.1	39
111	Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota. Nature Communications, 2018, 9, 5233.	5.8	40
112	Infections Ã Clostridium difficile. Revue Francophone Des Laboratoires, 2018, 2018, 48-56.	0.0	1
113	Clostridioides difficile Infection. Annals of Internal Medicine, 2018, 169, ITC49-ITC64.	2.0	89
114	Clostridium difficileinfection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hospital Practice (1995), 2018, 46, 266-277.	0.5	17
115	Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1309-1317.	0.8	48
116	Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. Surgical Infections, 2018, 19, 785-791.	0.7	6
117	Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Research, 2018, 7, 661.	0.8	7
118	An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection. MSphere, 2018, 3, .	1.3	21
119	Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C.) Tj ETQq1 1 0.784314 rgBT /Over	1.0	6
120	Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in Therapy, 2018, 35, 1920-1934.	1.3	17
121	Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease. Gastroenterology, 2018, 155, 1270-1271.	0.6	12

#	Article	IF	Citations
122	Clinical review of Clostridium difficile infection: an update on treatment and prevention. Expert Opinion on Pharmacotherapy, 2018, 19, 1759-1769.	0.9	20
123	The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection, 2018, 100, S1-S31.	1.4	38
124	Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. Journal of Infection and Chemotherapy, 2018, 24, 907-914.	0.8	18
125	Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics: Targets and Therapy, 2018, Volume 12, 11-21.	3.0	44
126	The role of vaccines in fighting antimicrobial resistance (AMR). Human Vaccines and Immunotherapeutics, 2018, 14, 2142-2149.	1.4	95
127	Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2018, 73, 2524-2528.	1.3	18
129	Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe, 2018, 53, 74-81.	1.0	25
130	Metronidazol en la prevenciÃ³n de diarrea asociada a antibiÃ³ticos e infecciÃ³n por Clostridium difficile en pacientes hospitalizados de alto riesgo. GastroenterologÃa Y HepatologÃa, 2018, 41, 362-368.	0.2	5
131	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. Jammi, 2018, 3, 71-92.	0.3	9
133	Host-Pathogen Interactions in Pathophysiology of Diarrheal Disorders. , 2018, , 1547-1577.		3
134	Prevention and Treatment of Clostridium difficile Enterocolitis. Advances in Surgery, 2018, 52, 29-42.	0.6	2
135	Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools. Current Infectious Disease Reports, 2018, 20, 32.	1.3	10
136	Management of Primary and Recurrent Clostridium difficile Infection: An Update. Antibiotics, 2018, 7, 54.	1.5	11
137	Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model. Frontiers in Microbiology, 2017, 8, 2635.	1.5	61
138	Clostridium difficile â€“ From Colonization to Infection. Frontiers in Microbiology, 2018, 9, 646.	1.5	118
139	A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile. Frontiers in Microbiology, 2018, 9, 1206.	1.5	17
140	Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection. Frontiers in Microbiology, 2018, 9, 1382.	1.5	6
141	Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections. Antibodies, 2018, 7, 5.	1.2	42

#	Article	IF	Citations
142	Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes. Journal of Antimicrobial Chemotherapy, 2018, 73, 2851-2855.	1.3	19
143	Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting. Infection Control and Hospital Epidemiology, 2018, 39, 924-930.	1.0	23
144	A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection. Journal of Visualized Experiments, 2018, , .	0.2	2
145	Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1035-1044.	4.6	65
146	Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiology and Infection, 2018, 146, 1101-1105.	1.0	18
147	Prevention and Treatment of Clostridium difficile-Associated Diarrhea in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America, 2018, 32, 733-748.	1.9	9
148	Current clostridium difficile treatments: Lessons that need to be learned from the clinical trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2874-2875.	1.4	0
149	The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67, 1920-1941.	6.1	248
150	Role of Immunoglobulin Therapy to Prevent and Treat Infections. , 2018, , 339-358.		7
151	Clostridium difficile infection and antibiotic-associated diarrhoea. Clinical Medicine, 2018, 18, 237-241.	0.8	114
152	Emerging Trends in Clinical Research With Implications for Population Health and Health Policy. Milbank Quarterly, 2018, 96, 369-401.	2.1	5
153	Basics of Immunoglobulins as Effector Molecules and Drugs. , 2018, , 133-150.		0
154	Bezlotoxumab for the Prevention of Clostridium difficile Recurrence. The Consultant Pharmacist, 2018, 33, 89-97.	0.4	4
155	Metronidazole in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection in high-risk hospitalised patients. GastroenterologÃa Y HepatologÃa (English Edition), 2018, 41, 362-368.	0.0	1
156	Current updates in management of Clostridium difficile infection in cancer patients. Current Medical Research and Opinion, 2019, 35, 473-478.	0.9	6
157	Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota. Human Vaccines and Immunotherapeutics, 2019, 15, 1453-1456.	1.4	7
158	Significant Publications on Infectious Diseases Pharmacotherapy in 2017. Journal of Pharmacy Practice, 2019, 32, 534-545.	0.5	8
159	Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent RecurrentClostridioides difficileInfection. Clinical Infectious Diseases, 2019, 68, 498-500.	2.9	14

#	Article	IF	Citations
160	Bezlotoxumab. Clinical Infectious Diseases, 2019, 68, 699-704.	2.9	39
161	Tutorial on Diarrhea and Enteral Nutrition: A Comprehensive Stepâ€Byâ€Step Approach. Journal of Parenteral and Enteral Nutrition, 2019, 43, 1008-1019.	1.3	10
162	Clostridioides difficile: diagnosis and treatments. BMJ: British Medical Journal, 2019, 366, l4609.	2.4	70
163	Clostridioides difficile therapeutics: guidelines and beyond. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611986854.	1.1	6
164	Systematic Review of Current Treatment and Prevention Strategies for Clostridium difficile. Current Emergency and Hospital Medicine Reports, 2019, 7, 66-73.	0.6	0
165	Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. Open Forum Infectious Diseases, 2019, 6, .	0.4	8
166	Structure of the full-length Clostridium difficile toxin B. Nature Structural and Molecular Biology, 2019, 26, 712-719.	3.6	59
167	Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1947-1952.	1.3	29
168	Microgels Sopping Up Toxinsâ€"GM1a-Functionalized Microgels as Scavengers for Cholera Toxin. ACS Applied Materials & Interfaces, 2019, 11, 25017-25023.	4.0	12
169	Infections in the Elderly Critically-Ill Patients. Frontiers in Medicine, 2019, 6, 118.	1.2	75
170	Management of Clostridioides difficile Infection. Critical Care Nurse, 2019, 39, e1-e12.	0.5	2
171	Repurposing auranofin as a Clostridioides difficile therapeutic. Journal of Antimicrobial Chemotherapy, 2020, 75, 409-417.	1.3	19
172	Updates in Treatment of Recurrent Clostridium difficile Infection. Journal of Clinical Medicine Research, 2019, 11, 465-471.	0.6	44
173	Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients. Transplant Infectious Disease, 2019, 21, e13184.	0.7	10
174	Risk for Clostridiodes difficile Infection among Older Adults with Cancer. Emerging Infectious Diseases, 2019, 25, .	2.0	5
175	Fecal microbiota transplantation (FMT) for C.Âdifficile infection, just say â€˜Noâ€™. Anaerobe, 2019, 60, 102092.	1.0	29
177	Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection. Hospital Pharmacy, 2019, 54, 294-299.	0.4	3
178	New concepts in C. difficile management. British Medical Bulletin, 2019, 131, 109-118.	2.7	2

#	Article	IF	Citations
179	Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infectious Diseases, The, 2019, 19, 265-274.	4.6	41
180	Clostridium difficile infection trials: what is the primary endpoint?. Lancet Infectious Diseases, The, 2019, 19, 219-220.	4.6	2
181	Dismantling a Toxin to Disarm a Superbug. Trends in Pharmacological Sciences, 2019, 40, 155-156.	4.0	0
182	The Gut Microbiota Is Associated with Clearance of Clostridium difficile Infection Independent of Adaptive Immunity. MSphere, 2019, 4, .	1.3	26
183	Treatment of Recurrent Clostridium difficile Infection. JAMA - Journal of the American Medical Association, 2019, 321, 512.	3.8	5
184	Deciphering the domain specificity of C. difficile toxin neutralizing antibodies. Vaccine, 2019, 37, 3892-3901.	1.7	9
185	Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population. Infectious Disease Clinics of North America, 2019, 33, 447-466.	1.9	17
186	The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials. Anaerobe, 2019, 60, 102048.	1.0	7
187	Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B. PLoS Biology, 2019, 17, e3000311.	2.6	24
188	Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge. Infection and Immunity, 2019, 87, .	1.0	6
189	Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	47
190	Enterotoxic Clostridia:Clostridioides difficileInfections. Microbiology Spectrum, 2019, 7, .	1.2	12
191	Clostridium difficile Infection in Children. Advances in Pediatrics, 2019, 66, 263-280.	0.5	9
192	Laboratory comparison between cell cytotoxicity neutralization assay and ultrasensitive single molecule counting technology for detection of Clostridioides difficile toxins A and B, PCR, enzyme immunoassays, and multistep algorithms. Diagnostic Microbiology and Infectious Disease, 2019, 95, 20-24.	0.8	10
193	Disorders of the Colon and Rectum. Clinical Gastroenterology, 2019, , 173-192.	0.0	1
194	Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection. Advances in Therapy, 2019, 36, 2052-2061.	1.3	13
195	Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. Expert Review of Clinical Pharmacology, 2019, 12, 635-642.	1.3	30
196	Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. Science Advances, 2019, 5, eaaw1327.	4.7	57

#	Article	IF	Citations
197	Management ofClostridioides difficilecolitis: insights for the gastroenterologist. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984765.	1.4	18
199	Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clinical Transplantation, 2019, 33, e13564.	0.8	35
200	Current and future trends in clostridioides (clostridium) difficile infection management. Anaerobe, 2019, 58, 95-102.	1.0	20
201	New insights for vaccine development against Clostridium difficile infections. Anaerobe, 2019, 58, 73-79.	1.0	12
202	Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. Lancet Infectious Diseases, The, 2019, 19, e284-e294.	4.6	7
203	A Review of Mixed Strain Clostridium difficile Colonization and Infection. Frontiers in Microbiology, 2019, 10, 692.	1.5	12
204	Small-Molecule Inhibitors of Haemophilus influenzae IgA1 Protease. ACS Infectious Diseases, 2019, 5, 1129-1138.	1.8	10
205	Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Nonâ€“C. difficile Diarrhea. Clinical Infectious Diseases, 2020, 70, 1083-1093.	2.9	28
206	Future Antibacterial Strategies: From Basic Concepts to Clinical Challenges. Journal of Infectious Diseases, 2019, 220, 350-360.	1.9	87
207	Differential effects of Clostridium difficile toxins on ion secretion and cell integrity in human intestinal cells. Pediatric Research, 2019, 85, 1048-1054.	1.1	3
208	Emerging drugs for the treatment of clostridium difficile. Expert Opinion on Emerging Drugs, 2019, 24, 17-28.	1.0	11
209	mRNA: A Novel Avenue to Antibody Therapy?. Molecular Therapy, 2019, 27, 773-784.	3.7	55
210	2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World Journal of Emergency Surgery, 2019, 14, 8.	2.1	102
211	Status of vaccine research and development for Clostridium difficile. Vaccine, 2019, 37, 7300-7306.	1.7	31
212	Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease. Advances in Chronic Kidney Disease, 2019, 26, 30-34.	0.6	12
213	Use of ribaxamase (SYN-004), a Î²-lactamase, to prevent Clostridium difficile infection in Î²-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infectious Diseases, The, 2019, 19, 487-496.	4.6	58
214	Safety and efficacy of fecal microbiota transplant in 9 critically ill patients with severe and complicated <scp>Clostridium difficile</scp> infection with impending colectomy. Journal of Digestive Diseases, 2019, 20, 301-307.	0.7	15
215	Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1297-1305.	1.3	8

#	Article	IF	Citations
216	Clostridium difficile infection: review. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1211-1221.	1.3	391
218	Epitheliumâ€specific MyD88 signaling, but not DCs or macrophages, control acute intestinal infection with Clostridium difficile. European Journal of Immunology, 2019, 49, 747-757.	1.6	5
219	Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. Expert Opinion on Investigational Drugs, 2019, 28, 323-335.	1.9	5
220	Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents. Human Microbiome Journal, 2019, 11, 100052.	3.8	76
221	La recherche en stratÃ©gies antibactÃ©riennesÂ: nouvelles pistes, nouveaux enjeuxÂ?. Bulletin De L'Academie Nationale De Medecine, 2019, 203, 179-185.	0.0	1
222	Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	13
223	Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open, 2019, 9, e031145.	0.8	13
224	Enterotoxic Clostridia:Clostridioides difficileInfections. , 2019, , 991-1011.		0
225	Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027. MSphere, 2019, 4, .	1.3	17
226	Early Readmission Predicts Increased Mortality in Cirrhosis Patients After Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2019, 53, e322-e327.	1.1	9
227	20. Immunprophylaxe gegen die Antibiotika-assoziierte DiarrhÃ¶. , 2019, , 277-302.		0
228	Monoclonal antibody-based therapies for bacterial infections. Current Opinion in Infectious Diseases, 2019, 32, 210-216.	1.3	71
229	The current novel therapeutic regimens forClostridium difficileinfection (CDI) and the potentials of Traditional Chinese Medicine in treatment of CDI. Critical Reviews in Microbiology, 2019, 45, 729-742.	2.7	7
230	Prevention and treatment of recurrent Clostridioides difficile infection. Current Opinion in Infectious Diseases, 2019, 32, 482-489.	1.3	11
231	Growing consumption of antibiotics and epidemiology of Clostridioides difficile infections in Poland: A need to develop new solutions. Acta Microbiologica Et Immunologica Hungarica, 2020, 67, 79-86.	0.4	0
232	Nuts and Bolts of Fecal Microbiota Transplantation. Clinical Gastroenterology and Hepatology, 2019, 17, 345-352.	2.4	38
233	Comparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infection. Current Opinion in Gastroenterology, 2019, 35, 20-24.	1.0	6
234	Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	17

#	Article	IF	Citations
235	Hypoalbuminemia as predictor of recurrence of Clostridium difficile infection. Wiener Klinische Wochenschrift, 2019, 131, 68-74.	1.0	14
236	Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?. Digestive Diseases and Sciences, 2019, 64, 1668-1671.	1.1	24
237	Small-Molecule Allosteric Triggers of Clostridium difficile Toxin B Auto-proteolysis as a Therapeutic Strategy. Cell Chemical Biology, 2019, 26, 17-26.e13.	2.5	11
238	Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11, 100045.	3.8	7
239	Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review. Anaerobe, 2019, 55, 112-116.	1.0	6
240	Management of adult Clostridium difficile digestive contaminations: a literature review. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 209-231.	1.3	11
241	Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Annals of the New York Academy of Sciences, 2019, 1435, 110-138.	1.8	40
242	Impact of early-life events on the susceptibility to Clostridium difficile colonisation and infection in the offspring of the pig. Gut Microbes, 2019, 10, 251-259.	4.3	14
243	Analysis of Treatment Outcomes for Recurrent Clostridium difficile Infections and Fecal Microbiota Transplantation in a Pediatric Hospital. Pediatric Infectious Disease Journal, 2019, 38, 32-36.	1.1	23
244	Monoclonal antibodies as anti-infective products: a promising future?. Clinical Microbiology and Infection, 2019, 25, 60-64.	2.8	55
245	C. difficile Infection and Antibiotic Associated Diarrhea. , 2020, , 404-417.		0
247	The Impact of Actotoxumab Treatment of Gnotobiotic Piglets Infected With Different Clostridium difficile Isogenic Mutants. Journal of Infectious Diseases, 2020, 221, 276-284.	1.9	0
248	Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clinical Infectious Diseases, 2020, 71, 1140-1141.	2.9	5
249	Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. Clinical Infectious Diseases, 2020, 71, 81-86.	2.9	17
250	Recent developments in the management of recurrent Clostridioides difficile infection. Anaerobe, 2020, 62, 102108.	1.0	8
251	Assessment of Bezlotoxumab Immunogenicity. Clinical Pharmacology in Drug Development, 2020, 9, 330-340.	0.8	3
252	Natural Clostridioides difficile Toxin Immunization in Colonized Infants. Clinical Infectious Diseases, 2020, 70, 2095-2102.	2.9	27
253	Prediction of poor outcome in Clostridioides difficile infection: AÂmulticentre external validation of the toxin B amplification cycle. Anaerobe, 2020, 61, 102079.	1.0	2

#	Article	IF	Citations
254	Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection. Digestive Diseases and Sciences, 2020, 65, 1125-1133.	1.1	16
255	Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. Anaerobe, 2020, 61, 102098.	1.0	42
256	Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate. International Journal of Infectious Diseases, 2020, 90, 237-242.	1.5	20
257	Regression analysis of recurrentâ€eventâ€free time from multiple followâ€up windows. Statistics in Medicine, 2020, 39, 1-15.	0.8	1
258	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. Journal of Hospital Infection, 2020, 105, 319-324.	1.4	19
259	Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. Clinical Infectious Diseases, 2020, 71, 1102-1105.	2.9	12
260	Small Molecule Inhibitor Screen Reveals Calcium Channel Signaling as a Mechanistic Mediator of Clostridium difficile TcdB-Induced Necrosis. ACS Chemical Biology, 2020, 15, 1212-1221.	1.6	9
261	Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies. Vaccine, 2020, 38, 2077-2087.	1.7	2
262	Therapeutic Mechanism of Macrophage Inflammatory Protein 1 Î± Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice. Journal of Infectious Diseases, 2020, 221, 1623-1635.	1.9	11
263	Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. Anaerobe, 2020, 61, 102137.	1.0	6
264	Treatment ofClostridioides (Clostridium) difficileinfection. Annals of Medicine, 2020, 52, 12-20.	1.5	26
265	Infection in the Patient With Cancer. , 2020, , 544-564.e6.		4
266	Evolving Strategies to Manage Clostridium difficile Colitis. Journal of Gastrointestinal Surgery, 2020, 24, 484-491.	0.9	12
267	Patent evaluation of US2019338018 (A1) 2019-11-07 (antibody fragments for the treatment of) Tj ETQq1 1 0.784314 rgBT /Overloc	2.4	0
268	A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models. Frontiers in Microbiology, 2020, 11, 578903.	1.5	13
269	Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials. Open Forum Infectious Diseases, 2020, 7, ofaa248.	0.4	4
270	Analysis of C. difficile infectionâ€"related outcomes in European participants in the bezlotoxumab MODIFY I and II trials. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1933-1939.	1.3	7
271	Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B. Communications Biology, 2020, 3, 347.	2.0	42

#	Article	IF	Citations
272	Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies. Infectious Diseases and Therapy, 2020, 9, 481-494.	1.8	11
273	InfecciÃ³n recurrente por Clostridium difficile tratada con bezlotoxumab en un paciente trasplantado hepÃ¡tico. GastroenterologÃa Y HepatologÃa, 2021, 44, 720-721.	0.2	1
274	Anti-virulence strategies for Clostridioides difficile infection: advances and roadblocks. Gut Microbes, 2020, 12, 1802865.	4.3	10
275	Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	4
276	Utilizing antibiotics to prevent Clostridioides difficile infection: does exposure to a risk factor decrease risk? A systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 2735-2742.	1.3	0
277	Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive. Antibiotics, 2020, 9, 412.	1.5	12
278	Identification of Simplified Microbial Communities That Inhibit Clostridioides difficile Infection through Dilution/Extinction. MSphere, 2020, 5, .	1.3	15
279	Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes. Clinical Infectious Diseases, 2021, 73, e2616-e2624.	2.9	7
280	Enhanced Humoral Immune Responses against Toxin A and B of Clostridium difficile is Associated with a Milder Disease Manifestation. Journal of Clinical Medicine, 2020, 9, 3241.	1.0	1
281	Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI) . Journal of Experimental Pharmacology, 2020, Volume 12, 371-384.	1.5	10
282	Treatment issues in recurrentClostridioides difficileinfections and the possible role of germinants. FEMS Microbes, 2020, 1, .	0.8	3
283	A probiotic yeast-based immunotherapy against Clostridioides difficile infection. Science Translational Medicine, 2020, 12, .	5.8	61
284	Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem. Microorganisms, 2020, 8, 1640.	1.6	8
285	The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Frontiers in Immunology, 2020, 11, 1951.	2.2	102
287	A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile. Vaccines, 2020, 8, 470.	2.1	5
288	Diagnostic and therapy of severe Clostridioides difficile infections in the ICU. Current Opinion in Critical Care, 2020, 26, 450-458.	1.6	4
290	Developing Diagnostic and Therapeutic Approaches to Bacterial Infections for a New Era: Implications of Globalization. Antibiotics, 2020, 9, 916.	1.5	11
291	Protecting intubated patients from the threat of antimicrobial resistant infections with monoclonal antibodies. Lancet Microbe, The, 2020, 1, e191-e192.	3.4	2

#	Article	IF	Citations
292	Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice. Vaccines, 2020, 8, 638.	2.1	6
295	The health and economic burden of antimicrobial resistance. , 2020, , 23-44.		2
296	Tackling antimicrobial resistance in the community. , 2020, , 45-70.		2
297	The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206.		2
299	Tackling antimicrobial resistance in the hospital sector. , 2020, , 71-98.		0
300	Tackling antimicrobial resistance in the food and livestock sector. , 2020, , 99-124.		1
301	Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. , 2020, , 125-154.		0
302	Ensuring innovation for diagnostics for bacterial infection to combat antimicrobial resistance. , 2020, , 155-180.		0
303	Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection. Open Forum Infectious Diseases, 2020, 7, ofaa157.	0.4	12
304	Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment. MSphere, 2020, 5, .	1.3	13
305	A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients. Infectious Diseases in Clinical Practice, 2020, 28, 10-15.	0.1	2
306	Regulation, risk and safety of Faecal Microbiota Transplant. Infection Prevention in Practice, 2020, 2, 100069.	0.6	51
307	Intestinal bile acids directly modulate the structure and function of C. difficile TcdB toxin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6792-6800.	3.3	55
308	Monoclonal IgM Antibodies Targeting Candida albicans Hyr1 Provide Cross-Kingdom Protection Against Gram-Negative Bacteria. Frontiers in Immunology, 2020, 11, 76.	2.2	11
309	Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020. JAMA - Journal of the American Medical Association, 2020, 323, 1403.	3.8	24
310	Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients. Journal of Clinical Medicine, 2020, 9, 865.	1.0	6
311	Recurrent Clostridioides difficile Infections: Should We Respond More to Toxin B?. Clinical Infectious Diseases, 2020, 71, 87-88.	2.9	0
312	Diagnosis and treatment of Clostridioides difficile infection. Medicina ClÃnica (English Edition), 2020, 155, 30-35.	0.1	0

#	Article	IF	Citations
313	Composite Kernel Association Test (CKAT) for SNP-set joint assessment of genotype and genotype-by-treatment interaction in Pharmacogenetics studies. Bioinformatics, 2020, 36, 3162-3168.	1.8	3
314	Strategies to prevent adverse outcomes following Clostridioides difficile infection in the elderly. Expert Review of Anti-Infective Therapy, 2020, 18, 203-217.	2.0	3
315	Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer. Open Forum Infectious Diseases, 2020, 7, ofaa038.	0.4	8
316	New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae. Translational Research, 2020, 220, 14-32.	2.2	13
317	In Vitro Production and Immunogenicity of a Clostridium difficile Spore-Specific BclA3 Glycopeptide Conjugate Vaccine. Vaccines, 2020, 8, 73.	2.1	9
318	Clinical management of severe, fulminant, and refractoryClostridioides difficileinfection. Expert Review of Anti-Infective Therapy, 2020, 18, 323-333.	2.0	6
319	A time-to-event analysis of the exposureâ€"response relationship for bezlotoxumab concentrations and CDI recurrence. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 121-130.	0.8	4
320	Antibacterial lead compounds and their targets for drug development. , 2020, , 275-292.		6
321	Costâ€effectiveness analysis of fecal microbiota transplantation for recurrent <scp>Clostridium difficile</scp> infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1515-1523.	1.4	17
322	Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey . Patient Preference and Adherence, 2020, Volume 14, 33-43.	0.8	10
325	Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Review of Anti-Infective Therapy, 2020, 18, 669-676.	2.0	15
326	Guidelines for Clostridium difficile infection in adults. Przeglad Gastroenterologiczny, 2020, 15, 1-21.	0.3	20
327	Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion. Infection and Immunity, 2020, 88, .	1.0	12
328	Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens. Antibiotics, 2020, 9, 155.	1.5	83
329	Guideline Recommendations: Optimal Timing of Publication and Resulting Rate of Adoption. Clinical Infectious Diseases, 2021, 72, 1950-1951.	2.9	2
330	Diarrhea in the pediatric solid organ transplantation recipient: A multidisciplinary approach to diagnosis and management. Pediatric Transplantation, 2021, 25, e13886.	0.5	5
331	A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. Journal of Internal Medicine, 2021, 289, 293-308.	2.7	8
332	Clostridium difficile toxin A and toxin B inhibit YAP in the colonic epithelial cells. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22652.	1.4	3

#	Article	IF	Citations
333	Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Translational Research, 2021, 230, 197-207.	2.2	5
334	Anti-toxin antibody is not associated with recurrent Clostridium difficile infection. Anaerobe, 2021, 67, 102299.	1.0	5
335	Defending against a difficult clostridioides with a vaccine. Lancet Infectious Diseases, The, 2021, 21, 157-158.	4.6	1
336	Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases, The, 2021, 21, 252-262.	4.6	38
337	Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110119.	1.4	7
338	Clostridioides-difficile-Infektion. , 2021, , 179-183.		0
339	Antibiotic-Associated Diarrhea and Update on Probiotics Recommendations. , 2021, , 141-166.		0
340	Clostridioides Difficile: Where Should the Management Strategies in Transplant Vary?. , 2021, , 519-543.		0
341	Challenges in the Diagnosis and Management of Recurrent and Severe Clostridioides difficile Infection in Children. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S27-S33.	0.6	2
342	Immune response against Clostridioides difficile and translation to therapy. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110148.	1.4	8
343	Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110186.	1.4	30
344	The Role of Vaccines in Combating Antimicrobial Resistance. Sustainable Agriculture Reviews, 2021, , 347-430.	0.6	3
345	Acute treatment with monoclonal antibodies: their design and their use. Microbiology Australia, 2021, 42, 39.	0.1	0
346	Clostridioides difficile Infection, Still a Long Way to Go. Journal of Clinical Medicine, 2021, 10, 389.	1.0	25
347	Teaching old mice new tricks: the utility of aged mouse models of C. difficile infection to study pathogenesis and rejuvenate immune response. Gut Microbes, 2021, 13, 1966255.	4.3	1
348	Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections. Nanoscale Horizons, 2021, 6, 330-340.	4.1	17
349	Nosocomial Infection. Critical Care Medicine, 2021, 49, 169-187.	0.4	82
350	Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199404.	1.4	12

#	Article	IF	Citations
352	Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms, 2021, 9, 306.	1.6	6
353	U.S. FDA Approved Drugs from 2015â€“June 2020: A Perspective. Journal of Medicinal Chemistry, 2021, 64, 2339-2381.	2.9	314
354	Systematic Evaluation of Parameters Important for Production of Native Toxin A and Toxin B from Clostridioides difficile. Toxins, 2021, 13, 240.	1.5	5
355	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Diseases of the Colon and Rectum, 2021, 64, 650-668.	0.7	7
356	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 879-913.	0.6	177
357	Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics, 2021, 10, 299.	1.5	23
358	Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Current Opinion in Gastroenterology, 2021, 37, 336-343.	1.0	18
359	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 147-163.	0.5	0
360	Clostridioides Difficile Infection: A comprehensive review for primary providers. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2021, 59, 262-269.	0.3	0
361	Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics. Journal of Global Antimicrobial Resistance, 2021, 24, 285-295.	0.9	54
362	Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies. Infectious Diseases and Therapy, 2021, 10, 853-870.	1.8	17
363	Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics. Frontiers in Medicine, 2021, 8, 641260.	1.2	4
364	Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!. Journal of Internal Medicine, 2021, 290, 294-309.	2.7	10
365	Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection. Infection and Immunity, 2021, 89, .	1.0	9
366	Strong Antimicrobial Effects of Xanthohumol and Beta-Acids from Hops against Clostridioides difficile Infection In Vivo. Antibiotics, 2021, 10, 392.	1.5	8
367	Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clinical Microbiology and Infection, 2021, 27, 1448-1454.	2.8	14
369	PrevenciÃ³n de las infecciones nosocomiales en reanimaciÃ³n. EMC - Anestesia-ReanimaciÃ³n, 2021, 47, 1-16.	0.1	0
370	Can sequencing improve the diagnosis and management of Clostridioides difficile infection?. Expert Review of Molecular Diagnostics, 2021, 21, 429-431.	1.5	1

#	Article	IF	Citations
371	Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. Journal of Clinical Medicine, 2021, 10, 1627.	1.0	4
372	Prevenzione delle infezioni nosocomiali in terapia intensiva. EMC - Anestesia-Rianimazione, 2021, 26, 1-14.	0.1	0
373	Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection. International Journal of Antimicrobial Agents, 2021, 57, 106311.	1.1	0
375	ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. American Journal of Gastroenterology, 2021, 116, 1124-1147.	0.2	218
376	Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents. Pathogens, 2021, 10, 649.	1.2	10
377	Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria. Frontiers in Pharmacology, 2021, 12, 673239.	1.6	19
378	Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection. Nature Communications, 2021, 12, 3748.	5.8	41
379	A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea. Gastroenterology Clinics of North America, 2021, 50, 323-340.	1.0	21
380	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases, 2021, 73, e1029-e1044.	2.9	270
382	Fecal Mycobiota Combined With Host Immune Factors Distinguish Clostridioides difficile Infection From Asymptomatic Carriage. Gastroenterology, 2021, 160, 2328-2339.e6.	0.6	22
383	Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, ofab294.	0.4	9
384	Clinical guidelines â€œChronic diarrhea in adultsâ€• Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 7-67.	0.1	5
385	Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scandinavian Journal of Gastroenterology, 2021, 56, 1056-1077.	0.6	12
386	Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?. Annals of Pharmacotherapy, 2022, 56, 441-462.	0.9	26
387	Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. Frontiers in Oncology, 2021, 11, 685320.	1.3	3
388	Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intestinal Research, 2021, 19, 265-274.	1.0	23
389	How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clinical Microbiology and Infection, 2021, 27, 1777-1783.	2.8	15
390	Recent advances in Clostridioides difficile infection epidemiology, diagnosis and treatment in children. Current Opinion in Infectious Diseases, 2021, 34, 527-532.	1.3	3

#	Article	IF	Citations
391	The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients. Frontiers in Immunology, 2021, 12, 691039.	2.2	9
392	Pharmacological Management of Pediatric Clostridioides difficile Infection: Clarifying the Controversies. Journal of Pediatric Health Care, 2021, , .	0.6	0
393	Antimicrobial stewardship and infection prevention interventions targeting healthcare-associated Clostridioides difficile and carbapenem-resistant Klebsiella pneumoniae infections: a scoping review. BMJ Open, 2021, 11, e051983.	0.8	10
394	Large Clostridial Toxins: Mechanisms and Roles in Disease. Microbiology and Molecular Biology Reviews, 2021, 85, e0006421.	2.9	42
395	Gastrobodies are engineered antibody mimetics resilient to pepsin and hydrochloric acid. Communications Biology, 2021, 4, 960.	2.0	6
396	My Treatment Approach to Clostridioides difficile Infection. Mayo Clinic Proceedings, 2021, 96, 2192-2204.	1.4	12
397	Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients. Journal of Infection and Public Health, 2021, 14, 1642-1649.	1.9	12
399	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases, 2021, 73, 755-757.	2.9	105
400	A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany. BMC Health Services Research, 2021, 21, 939.	0.9	3
401	The impact of human vaccines on bacterial antimicrobial resistance. A review. Environmental Chemistry Letters, 2021, 19, 4031-4062.	8.3	21
402	Monoclonal antibodies as antibacterial therapies: thinking outside of the box. Lancet Infectious Diseases, The, 2021, 21, 1201-1202.	4.6	7
403	Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe, 2021, 71, 102441.	1.0	6
404	Clostridioides (Clostridium) difficile. Medicine, 2021, 49, 643-647.	0.2	0
405	Subunit-based vaccines. , 2022, , 79-135.		2
406	Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266.		2
407	Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes, 2021, 13, 1-18.	4.3	35
408	OUP accepted manuscript. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S8-S15.	0.6	0
409	Prophylaxis of CDI. , 2021, , 79-81.		0

#	Article	IF	Citations
410	The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110202.	1.4	13
411	Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clinical Infectious Diseases, 2022, 74, 1572-1578.	2.9	14
412	Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110162.	1.4	37
413	Clostridium (Now Clostridioides) difficile-Associated Disease. , 2021, , 1713-1731.		0
414	Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings, 2020, 95, 758-769.	1.4	31
415	Challenges to Tackling Antimicrobial Resistance. , 2020, , .		11
416	Plasmid-mediated metronidazole resistance in Clostridioides difficile. Nature Communications, 2020, 11, 598.	5.8	79
419	Laryngeal Chemoreflex in Health and Disease: A Review. Chemical Senses, 2020, 45, 823-831.	1.1	9
420	The role of vaccines in combating antimicrobial resistance. European Journal of Public Health, 2020, 30, .	0.1	2
421	Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study. Open Forum Infectious Diseases, 2020, 7, ofaa097.	0.4	35
422	Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection. Journal of Clinical Gastroenterology, 2021, 55, 43-51.	1.1	11
424	Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection withClostridium Difficile(RAPID): a randomised placebo controlled trial. Gut, 2019, 68, 1224-1231.	6.1	23
425	Human C. difficile toxinâ€“specific memory B cell repertoires encode poorly neutralizing antibodies. JCI Insight, 2020, 5, .	2.3	8
426	Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Faculty Reviews, 2020, 9, 13.	1.7	10
427	Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B. PLoS Pathogens, 2020, 16, e1009181.	2.1	35
428	Serum-Derived Bovine Immunoglobulin as Novel Adjunct in Complicated Clostridium difficile Colitis Treatment. ACG Case Reports Journal, 2017, 4, e64.	0.2	1
429	New FDA approved antibacterial drugs: 2015-2017. Discoveries, 2018, 6, e81.	1.5	32
430	Diarrhea in adults. Clinical guidelines. Project. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 4-41.	0.1	3

#	Article	IF	Citations
431	Diarrhea when COVID-19 in adults. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 42-54.	0.1	4
432	The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile. Journal of Clinical Medicine, 2021, 10, 96.	1.0	4
433	Clostridium difficile Infection: an update on treatment and prevention. Vnitrni Lekarstvi, 2020, 66, e24-e28.	0.1	4
434	Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spaish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Revista Espanola De Quimioterapia, 2020, 33, 151-175.	0.5	13
435	An inventory of medicinal products causing skin rash: Clinical and regulatory lessons. Experimental and Therapeutic Medicine, 2019, 18, 5061-5071.	0.8	8
436	Recurrent Clostridioides difficile infection: Recognition, management, prevention. Cleveland Clinic Journal of Medicine, 2020, 87, 347-359.	0.6	11
437	New and promising anti-bacterials: Can this promise be sustained?. Journal of Anaesthesiology Clinical Pharmacology, 2020, 36, 13.	0.2	1
438	RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention. Gut and Liver, 2019, 13, 16-24.	1.4	106
439	The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview. Cureus, 2019, 11, e3977.	0.2	43
440	Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge. Cureus, 2020, 12, e9629.	0.2	18
441	European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection, 2021, 27, S1-S21.	2.8	242
442	Anti-virulence Therapy Against Bacterial Infections: Mechanisms of Action and Challenges. Journal of Kermanshah University of Medical Sciences, 2021, 25, .	0.1	1
443	In vitro and in vivo anti-Clostridioides difficile effect of a probiotic Bacillus amyloliquefaciens strain. Journal of Microbiology and Biotechnology, 2021, 31, .	0.9	3
444	Can prediction scores be used to identify patients at risk of Clostridioides difficile infection?. Current Opinion in Gastroenterology, 2021, Publish Ahead of Print, 7-14.	1.0	1
445	Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clinical Microbiology and Infection, 2022, 28, 321-331.	2.8	22
446	Gastrointestinal Infections: Case-Based Learning. , 2017, , .		0
447	Gastrointestinal Infections: Travelers' Diarrhea and Clostridioides Difficile Infection. , 2017, , .		0
448	InfektiÃ¶se Darmerkrankungen. , 2018, , 279-320.		0

#	Article	IF	Citations
449	Modern approach to the therapy of infections caused by Clostridium difficile. Racionalna Terapija, 2018, 10, 25-31.	0.1	0
451	V. Clostridioides Difficile Infection. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 2261-2268.	0.0	1
452	Neue Arzneimittel 2018. , 2019, , 61-175.		1
454	Risk, Outcomes, and Trends of Clostridium Difficile Infection in Multiple Myeloma Patients from a Nationwide Analysis. Cureus, 2019, 11, e4391.	0.2	6
456	Gastrointestinale Infektionen: Steigende Hospitalisierungs- und MortalitÄtsraten. Deutsches Ärzteblatt International, 0, , .	0.6	0
458	New Strategies against <i>Clostridioides Difficile</i> Infections. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1469-1474.	0.0	0
459	Clinical Guideline Highlights for the Hospitalist: Clostridium difficile Infections in Children. Journal of Hospital Medicine, 2020, 15, 98-100.	0.7	0
460	Immunopathogenesis, Immunization, and Treatment of Infectious Diseases. , 2020, , 277-319.		0
461	Clostridium (Now Clostridioides) difficile-Associated Disease. , 2020, , 1-19.		0
462	Stories of drug repurposing for pancreatic cancer treatmentâ€"Past, present, and future. , 2020, , 231-272.		1
464	Place de la transplantation de microbiote fÃ©cal dans lâ€™infection Ã Clostridium difficile. Colon and Rectum, 2020, 14, 88-93.	0.0	0
465	The Face of Clostriodes Difficile Infections in the Outpatient Setting. Spartan Medical Research Journal, 2020, 5, 12883.	0.3	0
468	Tackling antimicrobial resistance in the community. European Journal of Public Health, 2020, 30, .	0.1	0
469	Recurrent Clostridium difficile infection treated with bezlotoxumab in a liver transplant patient. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 720-720.	0.0	1
470	Prevention of Infection due to Clostridium (Clostridioides) difficile. Infectious Disease Clinics of North America, 2021, 35, 995-1011.	1.9	5
471	Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. Journal of Clinical Medicine, 2021, 10, 2.	1.0	21
474	Immunotherapy and vaccination against infectious diseases. Wiener Klinische Wochenschrift, 2021, 133, 714-720.	1.0	2
475	Clostridioides Difficile Infection. Diseases of the Colon and Rectum, 2021, 64, 151-155.	0.7	0

#	Article	IF	Citations
476	Clostridium difficile. , 2020, , 1115-1120.		0
477	Clostridioides Difficile: Where Should the Management Strategies in Transplant Vary?. , 2020, , 1-26.		0
478	The role of civil society in tackling antimicrobial resistance. , 2020, , 207-240.		0
481	How I manage infection risk and prevention in patients with lymphoid cancer. Blood, 2022, 139, 1517-1528.	0.6	3
482	DiagnÃ³stico y tratamiento de la infecciÃ³n por Clostridioides difficile. Medicina ClÃnica, 2020, 155, 30-35.	0.3	3
486	South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. Southern African Journal of Infectious Diseases, 2020, 35, 219.	0.3	3
487	Evidence-Based Approach to Infection. Gastroenterology and Hepatology, 2017, 13, 238-241.	0.2	2
488	Bezlotoxumab (Zinplava) for Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. P and T, 2017, 42, 735-738.	1.0	15
489	Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results. Revista Espanola De Quimioterapia, 2018, 31, 411-418.	0.5	9
490	A comprehensive approach for the patient with Clostridium difficile infection. Revista Espanola De Quimioterapia, 2018, 31 Suppl 1, 27-31.	0.5	0
492	Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. Revista Espanola De Quimioterapia, 2019, 32 Suppl 2, 47-54.	0.5	3
493	Frontiers in antibiotic alternatives for Clostridioides difficile infection. World Journal of Gastroenterology, 2021, 27, 7210-7232.	1.4	5
494	Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nature Reviews Microbiology, 2022, 20, 285-298.	13.6	66
495	Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, S1-S16.	0.9	2
496	Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics. Current Treatment Options in Pediatrics, 2021, 7, 203-216.	0.2	1
497	Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development. FEBS Journal, 2023, 290, 962-969.	2.2	6
498	Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opinion on Therapeutic Targets, 2021, , 1-15.	1.5	5
499	Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome. Anaerobe, 2022, 73, 102502.	1.0	10

#	Article	IF	Citations
500	Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. European Journal of Public Health, 2020, 30, .	0.1	0
501	The health and economic burden of antimicrobial resistance. European Journal of Public Health, 2020, 30, .	0.1	1
502	Protease-stable DARPins as promising oral therapeutics. Protein Engineering, Design and Selection, 2021, 34, .	1.0	1
503	Fecal microbiota transplantation for recurrentClostridioides difficile, safety, and pitfalls. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110531.	1.4	15
504	Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives. ACS Infectious Diseases, 2022, 8, 433-456.	1.8	15
505	Impact of antibiotics on the human microbiome and consequences for host health. MicrobiologyOpen, 2022, 11, e1260.	1.2	169
506	Impairment of lysosomal function by Clostridioides difficile TcdB. Molecular Microbiology, 2022, 117, 493-507.	1.2	2
507	Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients. Journal of Pharmacy Practice, 2023, 36, 584-587.	0.5	5
508	Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection. Journal of Clinical Microbiology, 2022, 60, jcm0220121.	1.8	5
509	Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. Letters in Applied Microbiology, 2022, 75, 526-536.	1.0	6
510	Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics, 2022, 11, 200.	1.5	101
511	Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 1996-2002.	1.3	7
512	Clostridioides difficile: Current overview and future perspectives. Advances in Protein Chemistry and Structural Biology, 2022, 129, 215-245.	1.0	5
513	Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 028-038.	0.8	6
514	American Society for Transplantation and Cellular Therapy Series: #5â€”Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients. Transplantation and Cellular Therapy, 2022, 28, 225-232.	0.6	9
515	Bacterialâ€fungal interactions and their impact on microbial pathogenesis. Molecular Ecology, 2023, 32, 2565-2581.	2.0	13
516	How to: Clostridioides difficile infection in children. Clinical Microbiology and Infection, 2022, 28, 1085-1090.	2.8	14
517	Cost-effectiveness of Fecal Microbiota Transplantation for First RecurrentClostridioides difficileInfection. Clinical Infectious Diseases, 2022, 75, 1602-1609.	2.9	8

#	Article	IF	Citations
518	Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience. Revista Espanola De Quimioterapia, 2022, 35, 279-283.	0.5	5
519	Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence. Contemporary Clinical Trials, 2022, 116, 106756.	0.8	2
520	Microbiome Modulation as a Novel Strategy to Treat and Prevent Respiratory Infections. Antibiotics, 2022, 11, 474.	1.5	15
521	Targeting Clostridioides difficile: New uses for old drugs. Drug Discovery Today, 2022, 27, 1862-1873.	3.2	7
523	Host Immune Responses to Clostridioides difficile: Toxins and Beyond. Frontiers in Microbiology, 2021, 12, 804949.	1.5	19
524	Human Î±-Defensin-6 Neutralizes Clostridioides difficile Toxins TcdA and TcdB by Direct Binding. International Journal of Molecular Sciences, 2022, 23, 4509.	1.8	5
533	Structure-Based Design of Î±-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa. ACS Infectious Diseases, 2022, 8, 1010-1021.	1.8	7
534	Assessment of the incidence and etiology of nosocomial diarrhea in a medical ward in Iraq. Journal of Medicine and Life, 2022, 15, 132-137.	0.4	1
535	Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	1
536	Evolution of the murine gut resistome following broad-spectrum antibiotic treatment. Nature Communications, 2022, 13, 2296.	5.8	16
537	Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	2.0	4
538	SER-109 for Recurrent Clostridioides difficile Infection. New England Journal of Medicine, 2022, 386, 1956-1958.	13.9	1
539	How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?. Lancet Infectious Diseases, The, 2022, 22, e336-e340.	4.6	7
541	Concurrent and Subsequent Co-Infections of Clostridioides difficile Colitis in the Era of Gut Microbiota and Expanding Treatment Options. Microorganisms, 2022, 10, 1275.	1.6	2
542	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	21.5	68
543	Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician. Biologics: Targets and Therapy, 0, Volume 16, 67-83.	3.0	0
544	Global trends in gut microbiota and clostridioides difficile infection research: A visualized study. Journal of Infection and Public Health, 2022, 15, 806-815.	1.9	6
545	Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. Microorganisms, 2022, 10, 1315.	1.6	7

#	Article	IF	Citations
546	Stool Interleukin-1Î² Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea. Clinical Infectious Diseases, 2023, 76, e1467-e1475.	2.9	8
547	Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
548	Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective. Frontiers in Immunology, 0, 13, .	2.2	9
549	Treatment of Clostridioides difficile Infection. JAMA - Journal of the American Medical Association, 2022, 328, 881.	3.8	4
550	The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review. Cureus, 2022, , .	0.2	3
551	The past, present, and future of antibiotics. Science Translational Medicine, 2022, 14, .	5.8	124
552	Clostridioides Infection in Patients with Inflammatory Bowel Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2022, 80, 66-71.	0.2	0
553	Annals for Hospitalists Inpatient Notes - Clinical Pearlsâ€"Updates on Clostridioides difficile Infection for Hospitalists. Annals of Internal Medicine, 2022, 175, HO2-HO3.	2.0	0
555	Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection. Gut Microbes, 2022, 14, .	4.3	6
556	Systematic review of guidelines for the diagnosis and treatment of Clostridioides difficile infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
557	Is Three Company or a Crowd? Comparing and Contrasting U.S. and European Clostridioidesdifficile Clinical Practice Guidelines. Antibiotics, 2022, 11, 1247.	1.5	1
558	The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021. Antibiotics, 2022, 11, 1211.	1.5	6
559	SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics, 2022, 11, 1234.	1.5	15
561	From signal transduction to protein toxinsâ€"a narrative review about milestones on the research route of C. difficile toxins. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396, 173-190.	1.4	3
562	Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections. Vaccines, 2022, 10, 1789.	2.1	9
563	The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic. European Respiratory Review, 2022, 31, 220068.	3.0	18
564	Bezlotoxumab in Patients with a Primary Clostridioides difficile Infection: A Literature Review. Antibiotics, 2022, 11, 1495.	1.5	4
565	Clostridium diffi cile infection and its eff ect on the course of infl ammatory bowel diseases. Klinicheskaia Meditsina, 2022, 100, 346-356.	0.2	0

#	Article	IF	Citations
566	Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?. Frontiers in Immunology, 0, 13, .	2.2	3
567	Comparative analysis and trends in liver transplant hospitalizations with clostridium difficile infections: A 10â€year national crossâ€sectional study. Transplant Infectious Disease, 0, , .	0.7	1
569	Severe Clostridioides difficile Infection in the Intensive Care Unitâ€"Medical and Surgical Management. Infectious Disease Clinics of North America, 2022, 36, 889-895.	1.9	1
570	Engineering the supernatural: monoclonal antibodies for challenging infectious diseases. Current Opinion in Biotechnology, 2022, 78, 102818.	3.3	2
571	Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipelineâ€"From Bench to Bedside. Applied Sciences (Switzerland), 2022, 12, 11615.	1.3	1
572	The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660. Infectious Diseases and Therapy, 2023, 12, 1-7.	1.8	6
573	Improving combination drug trials using â€˜definitive screening designsâ€™. Nature Biotechnology, 0, , .	9.4	0
574	Clostridioides difficile. , 2023, , 1024-1027.e2.		0
575	Approach to the Diagnosis and Management of Gastrointestinal Tract Infections. , 2023, , 388-395.e2.		0
576	The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211343.	1.4	14
577	Pathogenicity and virulence of Clostridioides difficile. Virulence, 2023, 14, .	1.8	24
578	Redistribution of the Novel Clostridioides difficile Spore Adherence Receptor E-Cadherin by TcdA and TcdB Increases Spore Binding to Adherens Junctions. Infection and Immunity, 2023, 91, .	1.0	2
579	Management ofClostridioides difficileinfection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. Journal of Antimicrobial Chemotherapy, 2023, 78, 21-30.	1.3	11
580	Paeniclostridium sordellii uterine infection is dependent on the estrous cycle. PLoS Pathogens, 2022, 18, e1010997.	2.1	2
581	<i>Clostridioides difficile</i> â€“ a new name, the old problems with diagnosis and treatment. AlÊ¹manah KliniÄeskoj Mediciny, 2023, 50, 377-391.	0.2	1
582	ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis. Frontiers in Microbiology, 0, 13, .	1.5	6
583	Genistein Inhibits Clostridioides difficile Infection via Estrogen Receptors and Lysine-Deficient Protein Kinase 1. Journal of Infectious Diseases, 2023, 227, 806-819.	1.9	3
584	Antibiotic-Associated Diarrhea Beyond C. Difficile: A Scoping Review. , 2023, 2, .		1

#	Article	IF	Citations
585	Powdery Mildew A Disease of Grapes And The Fungicides Mode of Action: A Review. Biosight Journal, 2022, 3, 38-52.	0.0	0
586	Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection. Open Forum Infectious Diseases, 2023, 10, .	0.4	5
587	Structure-guided design of a potent Clostridiodes difficile toxin A inhibitor. Frontiers in Microbiology, 0, 14, .	1.5	0
588	AWOT and CWOT for genotype and genotype-by-treatment interaction joint analysis in pharmacogenetics GWAS. Bioinformatics, 2023, 39, .	1.8	1
589	Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. Lancet Infectious Diseases, The, 2023, 23, e259-e265.	4.6	4
590	Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19. Anaerobe, 2023, 80, 102699.	1.0	0
591	A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent Clostridioides difficile infection. Expert Review of Anti-Infective Therapy, 2023, 21, 243-253.	2.0	6
592	Delivery of a therapeutic antibody to the lower gastrointestinal tract for the treatment of Clostridium difficile infection (CDI). Pharmaceutical Development and Technology, 2023, 28, 232-239.	1.1	0
593	Clostridioides difficile infection: traversing hostâ€“pathogen interactions in the gut. Microbiology (United Kingdom), 2023, 169, .	0.7	3
595	Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant. Clinical Therapeutics, 2023, 45, 356-362.	1.1	0
596	Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia. European Journal of Clinical Microbiology and Infectious Diseases, 2023, 42, 607-619.	1.3	3
597	Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode ofClostridioides difficileinfection treated with vancomycin. JAC-Antimicrobial Resistance, 2023, 5, .	0.9	0
598	Novel Biomarkers, Including tcdB PCR Cycle Threshold, for Predicting Recurrent Clostridioides difficile Infection. Infection and Immunity, 2023, 91, .	1.0	2
599	Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study. International Journal of Infectious Diseases, 2023, 131, 147-154.	1.5	1
600	How should we determine the role of bezlotoxumab for pediatric Clostridioides difficile infection?. Journal of the Pediatric Infectious Diseases Society, 0, , .	0.6	0
606	Clostridium Infections. , 2023, , 1227-1251.		0
615	Antibody Therapy as Alternative to Antibiotics. , 2023, , 34-53.		0
628	Using next generation antimicrobials to target the mechanisms of infection. , 2023, 1, .		0

#	Article	IF	Citations
634	Novel pharmaceutical approaches targeting antibiotic resistance. , 2023, , .		0
635	Quo vadis quorum sensing? Advances in disrupting the Pseudomonas quinolone signal (PQS). Annual Reports in Medicinal Chemistry, 2023, , .	0.5	0
644	Alternative therapeutic strategies to treat antibiotic-resistant pathogens. Nature Reviews Microbiology, 0, , .	13.6	2
650	Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future. Clinical Infectious Diseases, 2023, 77, S463-S470.	2.9	0
657	European Practice for CDI Treatment. Advances in Experimental Medicine and Biology, 2024, , 57-84.	0.8	0
659	Immunization Strategies Against Clostridioides difficile. Advances in Experimental Medicine and Biology, 2024, , 117-150.	0.8	1
664	Clostridioides difficile: from â€œdifficult to growâ€•to â€œdifficult to treatâ€• , 2024, , 945-956.		0
675	Unleashing the power of antibodies: Engineering for tomorrowâ€™s therapy. Advances in Protein Chemistry and Structural Biology, 2024, , .	1.0	0